TY - JOUR
T1 - Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis
AU - Wasse, Haimanot
AU - Huang, Rong
AU - Long, Qi
AU - Singapuri, Salman
AU - Raggi, Paolo
AU - Tangpricha, Vin
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Background: Vitamin D deficiency is highly prevalent among hemodialysis patients, but little data exist in support of an optimal repletion regimen. Objective: The objective was to ascertain the efficacy of weekly very-high-dose cholecalciferol (vitamin D3) in correcting vitamin D insufficiency and deficiency in patients with stage 5D chronic kidney disease. Design: We conducted a prospective, double-blind, randomized controlled pilot study that compared placebo with very high doses of oral cholecalciferol for 3 wk (200,000 IU/wk) in hemodialysis patients. We examined the rate of correction of vitamin D insufficiency or deficiency and the effect of treatment on markers of mineral metabolism and routine laboratory variables. Results: Twenty-seven subjects received placebo, and 25 received cholecalciferol. The majority (94%) of subjects had serum 25-hydroxyvitamin D [25(OH)D] concentrations <30 ng/mL. Study groups were similar with respect to baseline clinical characteristics, with the exception of hemoglobin concentrations, which were lower in the cholecalciferol-treated group (P < 0.04). At follow-up, 90.5% of subjects treated with cholecalciferol achieved serum 25(OH)D concentrations ≥30 ng/mL in contrast to 13.6% of the placebo group. There were no significant changes in serum calcium, phosphate, or intact parathyroid hormone during the study. Conclusion: Short-term, high-dose oral cholecalciferol treatment of vitamin D deficiency in hemodialysis patients appears to be effective and with no evidence of toxic effects. This trial was registered at clinicaltrials. gov as NCT00912782.
AB - Background: Vitamin D deficiency is highly prevalent among hemodialysis patients, but little data exist in support of an optimal repletion regimen. Objective: The objective was to ascertain the efficacy of weekly very-high-dose cholecalciferol (vitamin D3) in correcting vitamin D insufficiency and deficiency in patients with stage 5D chronic kidney disease. Design: We conducted a prospective, double-blind, randomized controlled pilot study that compared placebo with very high doses of oral cholecalciferol for 3 wk (200,000 IU/wk) in hemodialysis patients. We examined the rate of correction of vitamin D insufficiency or deficiency and the effect of treatment on markers of mineral metabolism and routine laboratory variables. Results: Twenty-seven subjects received placebo, and 25 received cholecalciferol. The majority (94%) of subjects had serum 25-hydroxyvitamin D [25(OH)D] concentrations <30 ng/mL. Study groups were similar with respect to baseline clinical characteristics, with the exception of hemoglobin concentrations, which were lower in the cholecalciferol-treated group (P < 0.04). At follow-up, 90.5% of subjects treated with cholecalciferol achieved serum 25(OH)D concentrations ≥30 ng/mL in contrast to 13.6% of the placebo group. There were no significant changes in serum calcium, phosphate, or intact parathyroid hormone during the study. Conclusion: Short-term, high-dose oral cholecalciferol treatment of vitamin D deficiency in hemodialysis patients appears to be effective and with no evidence of toxic effects. This trial was registered at clinicaltrials. gov as NCT00912782.
UR - http://www.scopus.com/inward/record.url?scp=84856376868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856376868&partnerID=8YFLogxK
U2 - 10.3945/ajcn.111.025502
DO - 10.3945/ajcn.111.025502
M3 - Article
C2 - 22237061
AN - SCOPUS:84856376868
VL - 95
SP - 522
EP - 528
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
SN - 0002-9165
IS - 2
ER -